Collaboration to develop and market vision analysis system

Article

Visiometrics and Medeuronet have formed together to develop and market Visiometrics' Optical Quality Analysis System (OQAS).

Visiometrics and Medeuronet have formed together to develop and market Visiometrics' Optical Quality Analysis System (OQAS).

Pan-European strategic commercial partner Medeuronet will market the system, created by Barcelona-based ophthalmic firm Visiometrics. OQAS is based on the works of Dr Pablo Artal, University of Murcia, Spain.

The system is based on the double-pass technique in which the punctual light source's size and shape projected onto the retina is analysed. The analysis will then provide the user with the point spread function (PSF), tear film quality, optical scattering index (OSI) and the modulation transfer function (MTF) of the eye.

Medeuronet aims to educate users on using the system in a clinical environment and how to make use of its benefits. The OQAS can be used to diagnose pathologies and compare pre and post-cataract and refractive surgery measurements and outcomes.

Other features of the OQAS include accommodation on retinal image quality, objective measurement of halos and glare and presenting the impact of higher-order aberrations and light scatter on visual acuity.

Visiometrics' Chief Executive Officer said, "We see this partnership with Medeuronet as a critical next step in the acceptance of OQAS on a wider commercial scale. We know that OQAS is the key tool to accurately and objectively assess the patient's quality of vision."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.